Associated Papers
A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors.
Oh HC et al.
Genome Biology, 2026
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Shiba-Ishii A et al.
Nature Cancer, 2022
Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
Ou SI et al.
Translational Oncology, 2021
A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.
Zhu VW et al.
Jto Clinical and Research Reports, 2021
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Takahashi K et al.
Thoracic Cancer, 2020
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Yoda S et al.
Cancer Discovery, 2018
Select a paper to view details